Skip to main content

Yesterday, Sept. 8, 2015, 65 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $218.00 to $671,295.90.

Highlighted Stocks Traded by Insiders:

Boston Private Financial Holdings (BPFH) - FREE Research Report

Deutsch Clayton, who is Ceo at Boston Private Financial Holdings, sold 30,000 shares at $11.80 on Sept. 8, 2015. Following this transaction, the Ceo owned 807,046 shares meaning that the stake was reduced by 3.58% with the 30,000-share transaction.

The shares most recently traded at $11.95, up $0.15, or 1.26% since the insider transaction. Historical insider transactions for Boston Private Financial Holdings go as follows:

  • 4-Week # shares bought: 8,500
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 8,500
  • 12-Week # shares sold: 43,583
  • 24-Week # shares bought: 8,500
  • 24-Week # shares sold: 87,117

The average volume for Boston Private Financial Holdings has been 487,900 shares per day over the past 30 days. Boston Private Financial Holdings has a market cap of $986.2 million and is part of the financial sector and banking industry. Shares are down 10.69% year-to-date as of the close of trading on Tuesday.

Boston Private Financial Holdings, Inc. operates as the bank holding company for Boston Private Bank & Trust Company that provides a range of banking and wealth management services. The stock currently has a dividend yield of 3.05%. The company has a P/E ratio of 17.4. Currently, there are 3 analysts who rate Boston Private Financial Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BPFH - FREE

TheStreet Quant Ratings

rates Boston Private Financial Holdings as a

TheStreet Recommends

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Boston Private Financial Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Access National (ANCX) - FREE Research Report

Taylor Margaret M, who is Senior Vice President, CFO at Access National, bought 75 shares at $19.88 on Sept. 8, 2015. Following this transaction, the Senior Vice President, CFO owned 3,935 shares meaning that the stake was boosted by 1.94% with the 75-share transaction.

The shares most recently traded at $20.40, up $0.52, or 2.55% since the insider transaction. Historical insider transactions for Access National go as follows:

  • 4-Week # shares bought: 1,003
  • 4-Week # shares sold: 2,910
  • 12-Week # shares bought: 1,003
  • 12-Week # shares sold: 2,910
  • 24-Week # shares bought: 2,254
  • 24-Week # shares sold: 16,695

The average volume for Access National has been 63,100 shares per day over the past 30 days. Access National has a market cap of $207.9 million and is part of the financial sector and banking industry. Shares are up 19.8% year-to-date as of the close of trading on Tuesday.

Access National Corporation operates as a bank holding company for Access National Bank that provides credit, deposit, mortgage, and wealth management services to small and medium sized businesses, professionals, and associated individuals primarily in the greater Washington, D.C. The stock currently has a dividend yield of 3.04%. The company has a P/E ratio of 12.9. Currently, there are 2 analysts who rate Access National a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANCX - FREE

TheStreet Quant Ratings

rates Access National as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Access National Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

iRadimed (IRMD) - FREE Research Report

Novovich Serge, who is Director at iRadimed, sold 600 shares at $24.67 on Sept. 8, 2015. Following this transaction, the Director owned 3,775 shares meaning that the stake was reduced by 13.71% with the 600-share transaction.

The shares most recently traded at $24.49, down $0.18, or 0.72% since the insider transaction. Historical insider transactions for iRadimed go as follows:

  • 4-Week # shares sold: 6,250
  • 12-Week # shares sold: 6,250
  • 24-Week # shares sold: 6,250

The average volume for iRadimed has been 35,900 shares per day over the past 30 days. iRadimed has a market cap of $269.6 million and is part of the health care sector and health services industry. Shares are up 91.01% year-to-date as of the close of trading on Tuesday.

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. The company has a P/E ratio of 122.3. Currently, there is 1 analyst who rates iRadimed a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRMD - FREE

TheStreet Quant Ratings

rates iRadimed as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full

iRadimed Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.